Sylvant (siltuximab) / Jazz, BeiGene  >>  Phase 2
Welcome,         Profile    Billing    Logout  

11 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sylvant (siltuximab) / Jazz
NCT01710241: A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma

Active, not recruiting
2
119
US, Europe, RoW
CNTO 328, Velcade, Melphalan, Prednisone
Janssen Research & Development, LLC
Multiple Myeloma
05/14
05/14
2006-005704-13: A Phase II Study of Intravenous CNTO328 in Patients with Recurrent Epithelial Ovarian Cancer

Ongoing
2
20
Europe
CNTO328, CNTO328,
Queen Mary, University of London
This is a Phase II trial to determine the efficacy of intravenous CNTO 328 in women with the following diseases:recurrent epithelial ovarian cancer, Fallopian tube carcinoma, primary peritoneal carcinoma of serous, endometrioid or clear cell sub-types.
 
 
2020-001413-20: Efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID-19 pneumonia Eficacia y seguridad de siltuximab vs. corticosteroides en pacientes hospitalizados con neumonía por COVID-19

Ongoing
2
100
Europe
Powder for concentrate for solution for infusion, Powder and solvent for solution for infusion, Sylvant, Urbason
Fundació Clínic per a la Recerca Biomèdica, IDIBAPS
COVID19 COVID19, Coronavirus Coronavirus, Diseases [C] - Virus Diseases [C02]
 
 
NCT03933904: Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Recruiting
2
24
US
Sirolimus, Rapamune, Rapamycin
University of Pennsylvania
Castleman Disease, Castleman's Disease, Multicentric
06/24
06/25
NCT06352866: Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Not yet recruiting
2
20
US
Siltuximab, Teclistamab(FDA-approved)
Jack Khouri
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
04/25
12/25
NCT06470971: Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Not yet recruiting
2
40
US
Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Anti-PD-1 Monoclonal Antibody, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment, Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, CNTO-328, Sylvant
Yuanquan Yang
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
12/25
12/25
NCT03315026: Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Active, not recruiting
2
30
US
Siltuximab, The M.D. Anderson Symptom Inventory (MDASI)
Memorial Sloan Kettering Cancer Center, Janssen Scientific Affairs, LLC
Multiple Myeloma, AL Amyloidosis
10/24
10/24
NCT04975555: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Recruiting
2
30
US
Siltuximab
University of Alabama at Birmingham
Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
12/24
12/25
STARFISH, NCT05684692: Screening Trial for Pain Relief in Schwannomatosis

Recruiting
2
40
US
Siltuximab, Sylvant, Erenumab-Aooe, Aimovig, Siltuximab Matching Placebo, Normal Saline, Erenumab-Aooe Matching Placebo
Massachusetts General Hospital, United States Department of Defense, Recordati Rare Diseases
Schwannomatosis, Schwannomas, Pain, Chronic
03/26
11/27
NCT04191421: Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Completed
1/2
42
US
Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, Sylvant, Spartalizumab, PDR001
Emory University, Novartis, EUSA Pharma, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
04/23
04/23
NCT02796859: Siltuximab in Schizophrenia

Recruiting
1/2
30
US
Siltuximab, Sylvant, normal saline, 0.9% NS
Brian Miller, Stanley Medical Research Institute
Schizophrenia, Psychotic Disorders
12/23
12/23

Download Options